Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates

被引：1
|
作者：
Vanhems, P [1 ]
Gaudet, R
Hirschel, B
Imrie, A
Conway, B
Rouleau, D
Vizzard, J
Perrin, L
Cooper, DA
Yerly, S
机构：
[1] Univ Lyon 1, INSERM U 271, Lab Epidemiol & Sante Publ, F-69365 Lyon, France
[2] Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, Canada
[3] Univ Hosp Geneva, Virol Lab, Geneva, Switzerland
[4] Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[5] Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada
来源：
AIDS | 2000年 / 14卷 / 08期
关键词：
D O I：
10.1097/00002030-200005260-00023
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1065 / 1067
页数：3
相关论文
共 50 条
  • [21] Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains
    Goudsmit, J
    Weverling, GJ
    van der Hoek, L
    de Ronde, A
    Miedema, F
    Coutinho, RA
    Lange, JMA
    Boerlijst, MC
    AIDS, 2001, 15 (17) : 2293 - 2301
  • [22] Emergence of dual resistance to zidovudine and lamivudine in clinical HIV-1 isolates from patients receiving zidovudine/lamivudine combination therapy
    Gass, RJA
    Shugarts, D
    Young, R
    Allen, M
    Rosandich, M
    Kuritzkes, DR
    ANTIVIRAL THERAPY, 1998, 3 (02) : 97 - 102
  • [23] ZALCITABINE COMPARED WITH ZIDOVUDINE IN PATIENTS WITH ADVANCED HIV-1 INFECTION WHO RECEIVED PREVIOUS ZIDOVUDINE THERAPY
    FISCHL, MA
    OLSON, RM
    FOLLANSBEE, SE
    LALEZARI, JP
    HENRY, DH
    FRAME, PT
    REMICK, SC
    SALGO, MP
    LIN, AH
    NAUSSKAROL, C
    LIEBERMAN, J
    SOO, WJ
    ANNALS OF INTERNAL MEDICINE, 1993, 118 (10) : 762 - 769
  • [24] Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates
    Duan, CY
    Poticha, D
    Stoeckli, TC
    Petropoulos, CJ
    Whitcomb, JM
    McHenry, CS
    Kuritzkes, DR
    JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (10): : 1336 - 1340
  • [25] ZIDOVUDINE IN THE MANAGEMENT OF PRIMARY HIV-1 INFECTION
    TINDALL, B
    GAINES, H
    IMRIE, A
    VONSYDOW, MAE
    EVANS, L
    STRANNEGARD, O
    TSANG, ML
    LINDBACK, S
    COOPER, DA
    AIDS, 1991, 5 (05) : 477 - 484
  • [26] ZIDOVUDINE CNS EFFECTS IN HIV-1 INFECTION
    BALDEWEG, T
    GRUZELIER, J
    LOVETT, E
    SCURLOCK, H
    RICCIO, M
    HAWKINS, D
    CATALAN, J
    INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY, 1994, 18 (02) : 92 - 93
  • [27] COMBINATION CHEMOTHERAPY FOR SENSITIVE AND RESISTANT HIV-1 ISOLATES
    HIRSCH, MS
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1991, 4 (03): : 316 - 316
  • [28] HIV-1 SENSITIVITY TO ZIDOVUDINE AND CLINICAL OUTCOME
    BOUCHER, CAB
    LANGE, JMA
    LANCET, 1992, 339 (8793): : 626 - 626
  • [29] Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection
    Anderson, PL
    Noormohamed, SE
    Henry, K
    Brundage, RC
    Balfour, HH
    Fletcher, CV
    PHARMACOTHERAPY, 2000, 20 (08): : 917 - 922
  • [30] SUSCEPTIBILITIES OF ZIDOVUDINE-SUSCEPTIBLE AND ZIDOVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS ISOLATES TO ANTIVIRAL AGENTS DETERMINED BY USING A QUANTITATIVE PLAQUE REDUCTION ASSAY
    LARDER, BA
    CHESEBRO, B
    RICHMAN, DD
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (03) : 436 - 441
12345